Application of Economics & Social Psychology to Improve Opioid Prescribing Safety (AESOPS): R21 Pilot Phase (AESOPS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03773484|
Recruitment Status : Enrolling by invitation
First Posted : December 12, 2018
Last Update Posted : April 4, 2019
|Condition or disease||Intervention/treatment||Phase|
|Opioid Use, Unspecified||Behavioral: Accountable Justification Behavioral: Active Choice (SmartSet) Behavioral: Audit and Feedback||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Application of Economics & Social Psychology to Improve Opioid Prescribing Safety (AESOPS): R21 Pilot Phase|
|Actual Study Start Date :||March 25, 2019|
|Estimated Primary Completion Date :||June 30, 2019|
|Estimated Study Completion Date :||August 2019|
Experimental: Clinical Decision Support/Audit & Feedback
Clinical decision support nudges (Accountable Justification and Active Choice (SmartSet)) within the electronic health record and Audit and Feedback on performance. Participating clinicians will receive any of three nudges when eligibility criteria are met within a patient's chart.
Behavioral: Accountable Justification
Accountable Justification is triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions.
Behavioral: Active Choice (SmartSet)
Active Choice (SmartSet) will be triggered within the EHR for patients with long-term opioid to encourage taper discussion, increase use of nonopioid alternatives, naloxone prescriptions and urine drug testing
Behavioral: Audit and Feedback
Clinicians will receive feedback on their performance during the prior quarter as well as how they compare to other clinicians on CDC measures of interest.
- Changes in daily milligram morphine equivalent [ Time Frame: 6 months ]We will estimate daily milligram morphine equivalent for each clinician and observe the change each month. This will capture CDC guideline prescribing endpoints.
- Rate of dose escalation [ Time Frame: 6 months ]Evaluate the transition from low to high dose prescribing
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03773484
|United States, Illinois|
|Chicago, Illinois, United States, 60611|
|Principal Investigator:||Jason N Doctor, PhD||University of Southern California|